[go: up one dir, main page]

FI933684L - Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution - Google Patents

Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution Download PDF

Info

Publication number
FI933684L
FI933684L FI933684A FI933684A FI933684L FI 933684 L FI933684 L FI 933684L FI 933684 A FI933684 A FI 933684A FI 933684 A FI933684 A FI 933684A FI 933684 L FI933684 L FI 933684L
Authority
FI
Finland
Prior art keywords
fluorcytosin
oxatiolan
hydroximethyl
antiviral
resolution
Prior art date
Application number
FI933684A
Other languages
English (en)
Other versions
FI114915B (fi
FI933684A0 (fi
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeng Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI933684(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Univ Emory filed Critical Univ Emory
Publication of FI933684A0 publication Critical patent/FI933684A0/fi
Publication of FI933684L publication Critical patent/FI933684L/fi
Application granted granted Critical
Publication of FI114915B publication Critical patent/FI114915B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
FI933684A 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi FI114915B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US65976091 1991-02-22
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US73608991A 1991-07-26 1991-07-26
US73608991 1991-07-26
US83115392A 1992-02-12 1992-02-12
US83115392 1992-02-12
US9201339 1992-02-20
PCT/US1992/001339 WO1992014743A2 (en) 1991-02-22 1992-02-20 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Publications (3)

Publication Number Publication Date
FI933684A0 FI933684A0 (fi) 1993-08-20
FI933684L true FI933684L (fi) 1993-09-06
FI114915B FI114915B (fi) 2005-01-31

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
FI933684A FI114915B (fi) 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi
FI20030932A FI20030932A7 (fi) 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20030932A FI20030932A7 (fi) 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi

Country Status (24)

Country Link
EP (3) EP0575482A1 (fi)
JP (2) JP2901160B2 (fi)
KR (1) KR0172590B1 (fi)
CN (4) CN1037682C (fi)
AT (2) ATE469147T1 (fi)
AU (2) AU679649B2 (fi)
BG (1) BG62053B1 (fi)
BR (1) BR9205661A (fi)
CA (2) CA2104399C (fi)
CZ (1) CZ295074B6 (fi)
DE (2) DE69233786D1 (fi)
DK (2) DK1439177T3 (fi)
ES (2) ES2345102T3 (fi)
FI (2) FI114915B (fi)
HU (2) HU227823B1 (fi)
IE (1) IE920545A1 (fi)
IL (1) IL100965A (fi)
MX (1) MX9200747A (fi)
MY (1) MY114350A (fi)
NO (3) NO312399B1 (fi)
NZ (2) NZ250842A (fi)
PT (1) PT100151B (fi)
RO (2) RO119365B1 (fi)
WO (1) WO1992014743A2 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
EP0674634B1 (en) * 1989-02-08 2003-04-16 Biochem Pharma Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
ES2286072T3 (es) * 1991-03-06 2007-12-01 Emory University Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
DK0639971T3 (da) * 1992-05-13 2000-03-20 Wellcome Found Terapeutiske kombinationer
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
EA001517B1 (ru) * 1996-06-25 2001-04-23 Глаксо Груп Лимитед Комбинации, содержащие vx478, зидовудин и 3tc, для применения при лечении вич
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
JP2001518899A (ja) 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
WO1999037754A2 (en) * 1998-01-26 1999-07-29 Pharm-Eco Laboratories, Inc. Enzyme activated supports for enantiomeric separations
IL138037A0 (en) 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
CN1141305C (zh) * 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
OA11741A (en) 1998-12-23 2005-05-13 Iaf Biochem Int Antiviral nucleoside analogues.
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
JP5105689B2 (ja) 2001-03-01 2012-12-26 ギリード・サイエンシズ・インコーポレーテッド 多形型および他の結晶型のシス−ｆｔｃ
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
AU2003285230B2 (en) * 2002-11-18 2010-04-22 Takeda Pharmaceutical Company Limited Stereoselective process for the production of dioxolane nucleoside analogues
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
AU2005329355B8 (en) * 2005-03-14 2012-02-23 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-Hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
BRPI0813237B8 (pt) 2007-06-18 2021-05-25 Sunshine Lake Pharma Co Ltd composto, método para preparar o composto, medicamento, e, uso do composto
US8350030B2 (en) 2007-12-07 2013-01-08 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2R, 5S)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
EP2258709A1 (en) 2008-02-29 2010-12-08 Kaneka Corporation 2'-hydroxyl-protected ribonucleoside derivative and manufacturing method of same
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
ES2524408T5 (es) 2010-11-19 2022-04-25 Gilead Sciences Inc Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
EP2846788A1 (en) 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4183792A4 (en) * 2020-07-14 2024-03-20 Sichuan University NITROGEN-CONTAINING 3-DESOXY-2-KETONE ACID DERIVATIVE, PRODUCTION PROCESS THEREOF AND USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
ES2286072T3 (es) 1991-03-06 2007-12-01 Emory University Sales de amidas de (-)cis 5 fluoro-2'-dedoxi-3'-tiacitidina utiles para el tratamiento de la hepatitis b.

Also Published As

Publication number Publication date
JP2901160B2 (ja) 1999-06-07
CA2104399C (en) 2005-10-18
CN1109108C (zh) 2003-05-21
PT100151A (pt) 1993-05-31
CN100396785C (zh) 2008-06-25
AU8077398A (en) 1998-10-15
DE69233379T2 (de) 2005-07-14
CN1418966A (zh) 2003-05-21
NO932980L (no) 1993-08-20
DE69233379D1 (de) 2004-08-05
DK0984013T3 (da) 2004-10-25
EP0984013B1 (en) 2004-06-30
DE69233786D1 (de) 2010-07-08
CN1203232A (zh) 1998-12-30
BR9205661A (pt) 1994-05-24
CN1127301A (zh) 1996-07-24
CN1084745C (zh) 2002-05-15
NO312399B1 (no) 2002-05-06
EP0984013A3 (en) 2000-08-02
CA2513440C (en) 2010-11-30
MX9200747A (es) 1992-09-01
NZ241625A (en) 1996-03-26
CA2104399A1 (en) 1992-08-23
WO1992014743A2 (en) 1992-09-03
HK1026419A1 (en) 2000-12-15
EP1439177B1 (en) 2010-05-26
ES2224547T3 (es) 2005-03-01
NO932980D0 (no) 1993-08-20
BG98062A (bg) 1994-04-29
DK1439177T3 (da) 2010-08-02
EP0984013A2 (en) 2000-03-08
CZ49792A3 (en) 1993-03-17
RO122814B1 (ro) 2010-02-26
NZ250842A (en) 1996-03-26
RO119365B1 (ro) 2004-08-30
CN1037682C (zh) 1998-03-11
HUT65548A (en) 1994-06-28
NO2005015I2 (no) 2007-10-01
WO1992014743A3 (en) 1992-10-29
AU665187B2 (en) 1995-12-21
ATE270291T1 (de) 2004-07-15
HU211344A9 (en) 1995-11-28
FI114915B (fi) 2005-01-31
FI20030932A7 (fi) 2003-06-24
CN1065065A (zh) 1992-10-07
BG62053B1 (bg) 1999-01-29
JP3292830B2 (ja) 2002-06-17
CA2513440A1 (en) 1992-09-03
HU9302377D0 (en) 1993-11-29
KR0172590B1 (ko) 1999-02-01
AU679649B2 (en) 1997-07-03
IL100965A (en) 1999-12-31
ES2345102T3 (es) 2010-09-15
NO2008010I1 (no) 2008-07-07
NO2005015I1 (no) 2005-07-11
JPH10147586A (ja) 1998-06-02
FI933684A0 (fi) 1993-08-20
EP1439177A1 (en) 2004-07-21
IE920545A1 (en) 1992-08-26
PT100151B (pt) 1999-09-30
CZ295074B6 (cs) 2005-05-18
ATE469147T1 (de) 2010-06-15
MY114350A (en) 2002-10-31
JPH06508605A (ja) 1994-09-29
EP0575482A1 (en) 1993-12-29
AU3794395A (en) 1996-03-14
HU227823B1 (en) 2012-03-28
IL100965A0 (en) 1992-11-15
AU1561792A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
FI933684L (fi) Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution
FI933888L (fi) Aertproteinhydrolysat, foerfarande foer dess framstaellning och anvaendningdaerav
FI920209L (fi) Saekerhetsdokument och dess framstaellningsfoerfarande.
FI911435A0 (fi) Antennstav och foerfarande foer dess framstaellning.
FI933294L (fi) Lamellartad polymerstomme och dess framstaellningsfoerfarande
FI933471A0 (fi) Polyhydroxikarboxylsyra och foerfarande foer dess framstaellning
FI920486L (fi) Bensimidazoler, dess foereningar innehaollande laekemedel och foerfarande foer deras framstaellning.
FI921326L (fi) Vattendispersion av sjaelvledande polyalkoxitiofener, foerfarande foer dess framstaellning och dess anvaendning
FI921333A0 (fi) Tvaodelad ostomianordning och dess koppling med gungande laosningskil.
FI931031L (fi) Mometasonfuroatmonohydrat, foerfarande foer dess framstaellning och farmaceutiska sammansaettningar
DE69202899D1 (de) Tintenstrahl-Druckknopf.
FI923629A0 (fi) Kopplingsstruktur med minst en kondensator och foerfarande foer dess framstaellning.
DE69217176D1 (de) Tastschalteranordnung
FI934470L (fi) Binaer praseodym-palladiumoxid, katalysatorkompositioner innehaollande denna, och metoder att anvaenda dessa
FI934820L (fi) Mjoelkchoklad och foerfarande foer dess framstaellning
FI924809L (fi) Dielektrisk resonatoranordning och foerfarande foer dess framstaellning
FI935522A7 (fi) Nitroglycerinplaoster och foerfarande foer dess framstaellning
FI921522L (fi) Pyrazolopyridinfoerening och foerfarande foer dess framstaellning
FI921919L (fi) Keramiskt bindemedel och dess anvaendning
FI912376A7 (fi) Antivirala aemnen.
FI923450L (fi) Universalprojektil och foerfarande foer dess framstaellning
FI934806L (fi) Jaestpromotor och dess anvaendning
FI914501L (fi) Majonaesprodukt med laog fetthalt och foerfarande foer dess framstaellning.
FI920762A0 (fi) Fuktkaensligt element och foerfarande foer dess framstaellning.
FI925833L (fi) Tricykliskt triazolderivat, dess framstaellning och dess anvaendning

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114915

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20050018

MA Patent expired